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Abstract   28 
Goal. The use of mesenchymal stem cells (MSC) as a therapeutic tool in cardiovascular 29 
diseases is promising. Since androgens exert some beneficial actions on the cardiovascular 30 
system, we tested our hypothesis that this hormone could promote MSC-mediated repair 31 
processes, also.  32 
Methods. Cultured MSC isolated from Wharton’s jelly were exposed to 30nM 33 
dihydrotestosterone (DHT) for 1 or 4 days and the effects of the hormone on their 34 
growth/migration/adhesion and the underlying mechanisms assessed. Results obtained by real 35 
time cell impedance measurements and DNA quantification showed that DHT increased MSC 36 
proliferation by ~30%. As determined by xCELLigence system, DHT-augmented (~2 folds) 37 
the migration of MSC towards cardiac tissue slices (at 12 hours) and this effect was blocked 38 
by Flutamide, an androgen receptor (AR) antagonist. Exposure of cells to DHT, up-regulated 39 
the gene and protein expression of AR, EMMPRIN, MMP-9 and down-regulated the 40 
expression of MMP-2. DHT significantly induced the release of nitric oxide by MSC (≥ 2-41 
fold) and Flutamide blocked this effect. When MSC were co-cultured with cardiac slices, 42 
immunohistochemical analysis and qRT-PCR showed that the integration of DHT-stimulated 43 
MSC was significantly higher than in controls. In conclusion, our findings provide the first 44 
evidence that DHT promotes MSC growth, migration and integration into the cardiac slices. 45 
The modulating effects of DHT were associated with up-regulation of ARs and of key 46 
molecules known to promote tissue remodeling and angiogenesis. Our findings suggest that 47 
priming of MSC with DHT may potentially increase their capability to regenerate cardiac 48 
tissue; in vivo studies are needed to confirm our in vitro findings.  49 
 50 
 51 
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  Introduction  52 
Heart disease is the leading cause of mortality and morbidity worldwide (Karantalis & 53 
Hare 2015). Although, multiple therapeutic, medical and surgical approaches have been 54 
developed to delay and treat the progression of the disease process, beside heart 55 
transplantation, a therapeutic approach for permanent cure of the damaged heart following 56 
myocardial infarction or heart failure remains elusive (Davis et al. 2000; Karantalis & Hare 57 
2015). Recent progress in stem cell research for tissue regeneration highlights the potential 58 
use of pluripotent adult stem/precursor cells to reconstruct or regenerate various tissues 59 
without comprising ethical issues (Nesselmann et al. 2008; Karantalis & Hare 2015; Singh et 60 
al. 2016). In this context, multipotent mesenchymal stem cells (MSC) which are capable of 61 
converting into different cell types have gained attention to serve as a therapeutic tool for 62 
permanently repairing/regenerating the damaged heart tissue. The MSC are of mesodermal 63 
origin and can differentiate into various cell types (endothelial cells, osteoblasts, chondrocyte, 64 
adipocyte, myocyte) when exposed to specific growth factors, signaling molecules and 65 
transcription factors (Karantalis & Hare 2015). More importantly, they can be cultured and 66 
primed for delivery in an in vitro setting (Karantalis & Hare 2015). MSC can be isolated from 67 
multiple sources (adipose tissue, placenta, gut, lung, liver, amniotic fluid, dental pulp, 68 
periodontal pulp, heart) (reviewed in ref 1). Taken together, the multiple tissue sources and 69 
pluripotent nature of MSC, together with the ease of in vitro expansion makes them an 70 
attractive therapeutic tool for treating heart damage.  71 
The last decade has seen multiple animal as well as clinical trials assessing the 72 
therapeutic potential of MSC in repairing cardiac damage and function (Nesselmann et al. 73 
2008; Singh et al. 2016). Although many (not all) studies have established the potential 74 
improvement in neovascularization, scar reduction and functional recovery, a major pitfall of 75 
MSC therapy is the low retention of transplanted cells, i.e. 0.44% of transplanted MSC 76 
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resided in myocardium after 4 days (Toma et al. 2002; Müller-Ehmsen et al. 2006).  This has 77 
led to a call for further optimization of MSC therapy by identifying molecules that could be 78 
used to prime/treat MSC or the recipient(s) to increase MSC homing in and retention (Ray & 79 
Novotny 2008). Since androgens have been shown to stimulate growth and influence 80 
cardiovascular cell’s activity (Liu et al. 2003; Ikeda et al. 2005), together with the fact that 81 
they promote growth and angiogenesis in progenitor endothelial cells and stem cells (Cai et 82 
al. 2016), we hypothesize that androgen(s) may also facilitate MSC growth and homing-in 83 
the heart tissue. Our hypothesis together with the fact that stem cell therapy is likely to be 84 
used in ageing men with low androgen levels (Gupta et al. 2008) may be od clinical relevance 85 
as pretreatment of recipients with androgen(s) may facilitate higher retention of transplanted 86 
cells.  87 
To test our hypothesis, in this study we assessed the effects of DHT, which is an 88 
androgen analog that is not converted to estrogen and selectively induces its biological effects 89 
via androgen receptors, on the growth, migration and integration of MSC into cardiac slices.  90 
Using MSC co-cultured with cardiac tissue slices we assessed the modulator effects of DHT 91 
on key actors (MMPs, VEGF-1, NO) of the pathways actively involved in tissue repair 92 
process such as proteolysis of fibrotic/scar tissue to promote MSC adhesion, 93 
angiogenesis/growth (proliferation, migration) and tissue repair. We report here that 94 
stimulation of MSC with DHT induces increased cell proliferation, migration and chemotaxis 95 
potentially via mechanism(s) involving ARs and MMPs, enhances cell migration towards the 96 
cardiac tissue slices and generate augmented secretion of Angiogenin, VEGF, and NO, factors 97 
involved in the invasion and integration of cells into ischemic tissues.  98 
 99 
 100 
 101 
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  Materials and methods 102 
Cell culture 103 
 Human MSC were isolated from Wharton’s Jelly (WJ) and characterized as 104 
previously described (Corotchi et al. 2013). All the procedures were approved by the 105 
Ethical Committee of the Institute of Cellular Biology and Pathology “Nicolae 106 
Simionescu”. Morphological characterization of the cells was done using an inverted 107 
microscope (Nikon Eclipse TE300, Nikon, Tokyo, Japan) and a digital camera system for 108 
imaging (Nikon Digital Net Camera DN100, Nikon). 109 
 110 
Adherence and Proliferation assays 111 
WJ-derived MSC were plated at a density of 25x104 cells per 75 cm2 flasks in the 112 
presence of 1, 30 and 100 nM DHT. The adherence and proliferation of DHT-treated MSC 113 
was determined in real-time using the xCELLigence and E-plate 16-View system (Roche, 114 
Basel, Switzerland). Briefly, after the cells were seeded onto the E-plate, various 115 
concentrations of DHT (AppliChem, GmbH) were added at time 0 and maintained for the 116 
entire period of the experiment. Automatically, the impedance values of each well were 117 
monitored by the xCELLigence system for 160 h. Based on cell impedance, the software 118 
monitored the cell index (CI) value, which is directly correlated with the cell number per 119 
well. We have used the RTCA DP 1.2.100 Software that allows to select different display 120 
possibilities and we choose a linear graphic (which skips the lag phase) for a 121 
representative evolution in time of the treatment dependent - cell proliferation rate. The 122 
experiments were done three times in duplicate.  123 
 To verify the results obtained from the proliferation assay and get an accurate measure of cell 124 
number, we applied for DNA determination using the CyQuant® Cell Proliferation Kit from 125 
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Thermo Fischer Scientific (Waltham, Massachusetts, USA), following the manufacturer 126 
instructions.   127 
 128 
Real-Time PCR technique 129 
The mRNA gene expression for Androgen Receptor (AR), EMMPRIN, MMP-2, 130 
MMP-9 and GAPDH was assessed by real-time PCR system (Applied Biosystems 131 
7900HT, Life Technologies, California, USA). Briefly, after 96 hours in culture of DHT- 132 
treated and non-treated MSC, total RNA was extracted using PureLink RNA Mini Kit 133 
(Life Technologies, California, USA). The RNA concentration was measured with a Nano 134 
Drop ND-1000 spectrophotometer (Thermo Fisher Scientific, CA, USA). The cDNA 135 
synthesis was done using 1 µg of total RNA. The cDNA samples were amplified (in 136 
triplicates) for 40 cycles (95°C for 2 min., 95°C for 5 secs, 60°C for 10 sec, 72°C for 15 137 
secs, and a dissociation cycle at 95°C for 15 secs and 60°C for 15 sec.) with specific 138 
oligonucleotide primers for AR, EMMPRIN, MMP-2, MMP-9 and GAPDH, as endogenous 139 
control. The primers used are shown in Table 1. As negative controls, unstimulated cells 140 
were employed. Data were expressed as means of fold expression (relative quantification) 141 
values and positive (±) SEM of each gene in comparison with non-treated MSC and 142 
normalized to an arbitrary value of 1. Significant p values were calculated from ΔΔCt 143 
values with ANOVA tests.   144 
 145 
Western blot assay 146 
MSC were cultured (96 hours) in the absence or presence of DHT (30 nM). After 147 
two washes in PBS, cell lysates were prepared using Pierce® Lysis Buffer, Halt Protease 148 
Inhibitor Single-Use Cocktail (Thermo Fisher Scientific, CA, USA) and a 10 minutes 149 
centrifugation at 14,000 g. Equal amounts of proteins from cell lysates were separated on 150 
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10–12% SDS-polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) under denaturing 151 
conditions and transferred onto Roti®-PVDF 2.0 membrane transfer (Carl Roth GmbH + 152 
Co. KG, Karlsruhe, Germany). Non-specific binding was blocked with 2% non-fat dry 153 
milk or BSA (2 h) in TBS (SantaCruz Biotechnology, TX, USA). The membranes were 154 
incubated overnight (at 4°C) with the following specific antibodies (dilution 1/1000): anti-155 
human AR: PA5-16750 (Thermo Fisher Scientific, CA, USA); anti human MMP-2: 156 
AV20016 and anti-human MMP-9: AV33090 (Sigma-Aldrich Chemie GmbH, Darmstadt, 157 
Germany); anti human VEGF: MAB293R, anti-human Angiogenin: AF265, and anti-158 
human EMMPRIN: AF972 (R&D Systems, MN, USA). After TBS washings, the 159 
membranes were incubated with the corresponding HRP-conjugated secondary antibodies: 160 
anti rabbit-HRP: AB6721(Abcam, Cambridge, UK); anti-mouse HRP: A9044 (Sigma-161 
Aldrich Chemie GmbH, Darmstadt, Germany), dilution 1/200, 1 hour at room temperature 162 
and examined by chemiluminescence (SuperSignal® West Femto Maximum Sensitivity 163 
Substrate, Thermo Fisher Scientific, CA, USA). For control of protein loading, anti-Beta-164 
actin antibody (Santa Cruz Biotechnology, TX, USA) was used. The blots were scanned 165 
using a bioimaging system (ImageQuant LAS-3000 Chemiluminescence & Fluorescence 166 
Imaging System, Fujitsu Life Sciences, Tokyo, Japan). Target signals were normalized 167 
against beta-actin and analyzed semi-quantitatively using the NIH Image system (ImageJ).   168 
 169 
Determination of NO produced by DHT-treated MSC  170 
These measurements were performed using the inNO-T system according to the 171 
published protocol (Alexandru et al. 2011).The NO released by MSC was measured after 172 
stimulation with 1, 30 and 100 nM DHT added at 10 min interval. In addition, to reveal 173 
the role of androgen receptors (AR) in DHT-induced NO liberation, the cultured MSC 174 
were stimulated for 45 minutes with an AR antagonist, Flutamide (Sigma-Aldrich Chemie 175 
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GmbH, Germany), then the medium was changed and the NO measurements were 176 
performed. 177 
 178 
Preparation of murine cardiac tissue slices   179 
Experiments were done accordingly to the guidelines of the local animal welfare 180 
committee and approved by the ethical commission of the Institute of Cellular Biology 181 
and Pathology “Nicolae Simionescu”. Under proper anesthesia, the hearts were removed 182 
from C57 Black mice and tissue slices were obtain using a vibratome apparatus according 183 
to Pillekamp et al. 2007. The sections were transferred in DMEM (1X) and GlutaMAX-I 184 
(LifeTechonlogy, NY, USA) containing 10% FBS (LifeTechonlogy, NY, USA) and kept 185 
in the incubator under normoxic conditions (37°C, 5% CO2, 21% O2). 186 
 187 
Evaluation of the interaction of MSC with cardiac tissue by chemotaxis assay 188 
xCELLigence system is a definite technique for real-time measurement of cell 189 
migration (Bird & Kirstein 2009). We employed CIM-plates which are composed of two 190 
chambers separated by a porous membrane. We placed in the lower chamber, one murine 191 
cardiac slice and in the upper chamber 40.000 MSC that were stimulated with DHT or 192 
exposed to the vehicle (controls). In both chambers DMEM (1X) with GlutaMAX® and 193 
10% FBS and 1% Antibiotic Antimycotic Solution (Sigma-Aldrich Chemie GmbH, 194 
Darmstadt, Germany) was used. The CIM-plates were kept in an incubator under 195 
normoxic conditions (as above). To evaluate the role of ARs in the migration process, 196 
MSC in the CIM plate system, were exposed to Flutamide for 45 minutes prior to the 197 
experiment. The cell migration was monitored for 12 hours. The determinations were done 198 
in quadruplicate and the experiments were repeated at least three times. 199 
 200 
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Analysis of proteins secreted by MSC upon interaction with cardiac tissue by ELISA 201 
and Luminex techniques   202 
For these experiments, 24 millimeters Transwell® with 0.4 µm pore polycarbonate 203 
membrane inserts, TC-treated (Corning, NY, USA) were used. Murine heart slices were 204 
placed in the lower chamber and 40000 MSC/well treated or not with DHT were placed in the 205 
upper chamber. Both, cells and tissues were maintained in DMEM medium (1X) with 206 
GlutaMAX® containing 10% FBS, 1% Antibiotic Antimycotic Solution and were kept in 207 
an incubator under normoxic conditions. For each experimental condition, after 24 and 48 208 
hours, 1,5 mL of conditioned medium was harvested from the lower chamber and MMP-2 209 
and MMP-9 determined by ELISA assay.   210 
Similar experiments were performed to assess Angiogenin and VEGF by Luminex 211 
technique using Human Angiogenic Panel A (BD Bioscience, CA, USA) according to the 212 
manufacturer’s protocols.  213 
 214 
Detection of MSC adherence and integration into cardiac tissue slices by 215 
immunohistochemistry 216 
In a 48 well plate TC treated (Corning, NY, USA), 250 µm thick murine heart slices 217 
were placed in DMEM medium (1X) with GlutaMAX®, 10% FBS CS and 1% Antibiotic 218 
Antimycotic Solution. Then, 40000 MSC/well non-treated or treated with DHT for 96 hours 219 
prior to co-cultivation, were seeded in direct contact with the heart slices. After 72 hours, the 220 
heart fragments were washed twice with PBS and subjected either to immunohistochemical 221 
staining or to DNA quantification for cell counting (see below). For immunohistochemistry, 222 
the heart fragments were fixed overnight in 4% paraformaldehyde, embedded in paraffin, 2 223 
µm sections cut with a microtome (DTK-2000, Dosaka, Kyoto, Japan), placed on slides, 224 
deparaffinized and rehydrated with successive concentrations of xylene and ethanol (100%, 225 
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95%, 70%, and 50%). To ease the binding of antibodies, the heat-induced epitope retrieval 226 
was performed by placing the sections kept in sodium citrate buffer in a pressure cooker for 3 227 
minutes. To evaluate the integration of human MSC in the murine ventricular slices we have 228 
employed anti-human nuclei antibody (1:100, Sigma-Aldrich Chemie GmbH, Darmstadt, 229 
Germany) followed by anti-mouse HRP: A9044 (Sigma-Aldrich Chemie GmbH, Darmstadt, 230 
Germany). As substrate for the detection system we used 3,3′-Diaminobenzidine (DAB) 231 
(Sigma-Aldrich Chemie GmbH, Darmstadt, Germany) that formed a brown color precipitate 232 
in the presence of HRP and H2O2. 233 
 234 
Determination of MSC adherence and integration into cardiac tissue slices by DNA 235 
quantification using qRT-PCR 236 
For these experiments, we have used Real time-PCR 7900 HT (as described above) 237 
TaqMan® Universal PCR Master Mix-4304437, Human GAPDH- Hs03929097_g1, and a 238 
384 well PCR plate (Thermo Fisher Scientific, CA, USA). Human MSC (40000 cells), 239 
untreated or DHT-treated (30 nM) were incubated as described above for 240 
immunocytochemistry experiments. After 48 hours, the DNA was isolated using the 241 
PureLink® Genomic DNA Minikit (Life Technologies) and quantified by Nanodrop® ND-242 
1000 UV–VIS spectrophotometer. For the calibration curve, serial 10-fold dilutions of 243 
standard DNA isolated from 2500 to 40000 MSC were prepared. Standard curves and the 244 
amplification conditions were established as in   Àlvarez et al. 2013. Also human versus 245 
mouse genes comparison was assayed using GenomeArtist (Ecovoiu et al. 2016)  246 
 The experimental conditions for the PCR were done according to the manufacturer 247 
specification. All experiments were performed in triplicate. 248 
 249 
 250 
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Liquid chromatography - mass spectrometry (LC-MS) analysis of MSC  251 
   All reagents were of electrophoresis or LC-MS grade. Urea, sodium deoxycholate 252 
(DOC), trizma hydrochloride (Tris-HCl), DL-dithiothreitol (DTT), iodoacetamide (IAA), N-253 
acetyl-L-cysteine (NAC), ammonium bicarbonate and MS solvents were from Sigma-Aldrich 254 
(Darmstadt, Germany). Trypsin Gold was from Promega (Wisconsin, USA), the protease 255 
inhibitors from Roche (Indiana, USA) and solid phase extraction C18 columns from Waters 256 
(Massachusetts, USA). ADV-01A kit from Tebu-Bio (Colorado, USA) was employed for 257 
protein quantification. The cells were washed twice with PBS, centrifuged and the pellet was 258 
solubilized in a denaturant buffer containing 8 M urea, 1% DOC, 0.1% Tris-HCl (pH 8.8) and 259 
protease inhibitors, using sonication pulses for 30 seconds, on ice (UP50H from Hielscher, 260 
Teltow, Germany). Protein purification, carbamydomethylation, proteolysis and solid phase 261 
extraction were performed as previously described (Suica et al. 2016). 262 
  LC-MS/MS analysis was carried out using the EASY n-LC II system (Thermo 263 
Scientific, California, USA) coupled to the LTQ Orbitrap Velos Pro mass spectrometer 264 
(Thermo Scientific), working in a Top12 data-dependent analysis, with 60k resolution, as 265 
described (Boteanu et al. 2016). Three biological replicates, each with three technological 266 
replicates were processed and analysed for the proteomics workflow. The bioinformatics 267 
analysis comprised database protein inference, relative quantification and Kyoto 268 
Encyclopaedia of Genes and Genomes (KEGG) signalling pathways over-representation and 269 
was performed as previously described (Uyy et al. 2016). 270 
 271 
Statistical analysis 272 
The data were analyzed by a one-way analysis of variance (ANOVA) either with the 273 
QtiPlot - 0.9.8.9 (ProIndep Serv S.R.L., Romania) or by a two-tailed unpaired t tests with the 274 
GraphPad Prism 4 software (GraphPad Software, Inc., La Jolla, CA, USA). The statistics are 275 
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presented as mean ± standard error of the mean and differences were considered statistically 276 
significant when p value < 0.05. 277 
 278 
  Results   279 
DHT augments MSC proliferation without affecting their morphology 280 
Since circulating levels of testosterone range between 8-42 nM/L, we first tested the 281 
effects of 1-1000nM of DHT on the growth of MSCs. Treatment of MSCs with 1-1000 nM 282 
DHT induced cell proliferation, but not cell death. Subsequently, we elected to use a 283 
concentration of 30nM, which is comparable to the circulating levels of testosterone and 284 
induced MSC growth with no toxicity.  Hence, this concentration was further used in most of 285 
the experiments. It must be emphasized that the circulating levels of DHT are 10-fold lower 286 
(≈ 3 nM) and its affinity for ARs is ≈ 3 fold higher than that of testosterone.  287 
Examination of MSC after 1 and 4 days in culture showed that the DHT-treated MSC 288 
exhibited a similar morphology and viability with the non-stimulated cells; however, a 289 
definite increase in cell density in stimulated cells compared to non-treated MSC was noticed 290 
(Fig. 1-A).  291 
 In addition, MSC proliferation was evaluated in real-time for 160 hours using 292 
xCELLigence system. In this system, the quantification of the cellular index (CI) calculated 293 
from the cellular impedance measurements is direct proportional with the number of cells per 294 
well. Our experiments revealed that DHT-treated MSC exhibited a significantly increased CI 295 
compared to non-treated cells indicating enhanced proliferation of MSC in the presence of 296 
DHT (Fig. 1-B).  297 
 To verify and confirm that CI correlates directly to the increase in cell number, we 298 
performed a proliferation assay consisting in DNA quantification. The results showed that 299 
DHT stimulation increased the number of MSC with more than 20,000 cells per well after 6 300 
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days in culture, which is a 3-fold increase compared to control, cells treated with DMSO 301 
(vehicle) (Fig. 1-C). The data corroborate well with those obtained using xCELLigence 302 
system, showing that DHT stimulation induces an increase in MSC proliferation rate.   303 
 304 
 DHT induces in MSC up-regulation of the gene expression of ARs and of the genes 305 
involved in cell migration, EMMPRIN and MMP-9 306 
To find out whether DHT affects the gene expression of ARs and of other molecules 307 
implicated in cell migration, cultured MSC were exposed to the hormone (30 nM) and then 308 
subjected to qRT-PCR assay. The experiments revealed that DHT induced a significant up-309 
regulation of the mRNA for AR and of the molecules involved in cell migration, EMMPRIN 310 
and MMP-9; DHT had no effect on MMP-2 gene expression (Fig. 2).  311 
 312 
DHT induces changes in protein expression of AR, EMMPRIN, Angiogenin and MMP-9 313 
  Western blot assay showed that, compared to non-stimulated cells, the DHT- treated 314 
MSC exhibit a significant increase in protein expression of ARs, EMMPRIN, Angiogenin and 315 
MMP-9. The expression of MMP-2 and VEGF were not modified by DHT as compared to the 316 
non-treated MSC (Fig. 3). Remarkably, the DHT-induced changes in the protein expression of 317 
AR, EMMPRIN and MMP9 were paralleled by comparable increased in their gene expression 318 
in MSCs (Fig. 2). 319 
DHT stimulates NO production in MSC via an AR mechanism  320 
These experiments examined whether the MSC respond to different DHT 321 
concentrations (1, 30 and 100 nM) by releasing increased concentration of NO in the culture 322 
medium; the NO production was monitored with a specific NO sensor. It was detected that, in 323 
the presence of different DHT concentrations, the MSC produced approx. 2.5-fold more NO 324 
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compared with the values (baseline) obtained for non-treated MSC and this was independent 325 
of the hormone concentrations (Fig. 4-a, b).  326 
In MSCs pretreated for 45 minutes with Flutamide (10 µM), an androgen receptor 327 
antagonist, the stimulatory effects of DHT on NO secretion were blocked to basal levels, 328 
suggesting that the stimulatory effects of DHT on NO secretion are AR mediated (Table 2).  329 
These observations provide evidence that the concentration-dependent stimulatory effects of 330 
DHT on NO secretion are AR mediated.  331 
 332 
DHT enhances migration of MSC towards the murine cardiac slices 333 
To find out whether DHT influences the migration of MSC toward heart tissue we set 334 
up co-culture experiments utilizing human MSC and murine cardiac tissue slices (250 µm 335 
thick). The results obtained using xCELLigence system showed that the rate of migration of 336 
hormone-treated MSC towards the cardiac tissue was constantly higher than the values 337 
obtained for migration of control, or vehicle–exposed cells. The migration of stimulated MSC 338 
was about two folds higher during, and at the end of the 14 hours of measurements. To find 339 
out if ARs are involved in cell migration towards heart, we performed similar experiments in 340 
the presence of Flutamide, to impair the hormone action by blocking its receptor (Fig. 5-a, b). 341 
The results showed that blocking the ARs, the cell migration, as expressed by the cell index, 342 
was limited to the values obtained in controls. 343 
 344 
DHT-treated MSC exhibit increased adherence/integration into cardiac slices 345 
 To validate the above results and achieve robust evidence of MSC migration and 346 
integration into murine cardiac slices, we apply for immunohistochemical staining using anti-347 
human nuclei antibody that could detect particularly human MSC within the sections.  348 
  
15 
Examination of the tissue sections incubated with anti-human nuclei antibody followed by an 349 
HRP-labeled secondary antibody revealed the brown-stained MSC nuclei and the blue, 350 
hematoxylin stained, mouse cell nuclei. We found that in comparison with non-treated MSC, 351 
the number of DHT-treated human MSC is considerably higher (Fig. 6-a, b). As antibody 352 
control we used IgG isotype (Fig. 6-c). The data were validated by digital counting using 353 
ImageJ software indicating a significant difference between non- and treated MSC integration 354 
within heart tissue (Fig. 6-d).  355 
Because of the limited volume of tissue that can be examined by 356 
immunocytochemistry, we apply for a quantitative method, the qRT-PCR. Evaluation of 357 
human DNA revealed that the total number of human hormone-treated MSC adhered and 358 
integrated within the cardiac slices was ~50% higher than for the non-stimulated cells (Fig. 6-359 
e).  360 
 361 
Incubation of DHT-treated MSC with heart tissue increases the cell secretion of MMP-2 362 
and MMP-9.   363 
To determine whether migration-stimulating factors are released after co-culture of 364 
stimulated MSC with cardiac slices, we employed a Transwell system in which the cells and 365 
the cardiac sections were placed in the upper and respectively lower chamber, that is in 366 
indirect contact. After 24 and 48 hours, the culture medium was collected and analyzed using 367 
human specific ELISA kits. We have detected that MMP-2 and MMP-9 were significantly 368 
increased, both at 24 and 48 hours of co-cultivation of DHT-treated MSC with cardiac slices 369 
as compared to controls in which non-treated MSC were employed. The difference was, in 370 
particular, higher after 48 h (Fig. 7-a-d).   371 
 372 
  
16 
Exposure of hormone-treated MSC to cardiac tissue slices up-regulates the cell secretion 373 
of Angiogenin and VEGF  374 
Analysis by fluorescence-based multiplex cytokine assay (Luminex) of the conditioned 375 
medium collected from DHT-treated MSC incubated (in a Transwell system) with cardiac 376 
tissue slices, revealed a significant up-regulated secretion of Angiogenin (at 24 and 48 hours), 377 
and of VEGF at 48h (Fig. 7-e, f).  378 
 379 
 380 
Up-regulation of actin cytoskeleton in DHT-treated MSC as revealed by liquid 381 
chromatography-mass spectrometry 382 
A total of 3180 protein groups were unambiguously identified using high resolution 383 
mass spectrometry, of which 2320 were identified in both groups, while 490 proteins could be 384 
uniquely attributed to the effects of DHT treatment on MSC (Fig 8-a). The relative 385 
quantification experiments were based on precursor ion alignment and intensity comparison 386 
between the DHT-treated and the control MSC. A coefficient of variation of <30% was 387 
allowed between technical replicates. The total ion chromatogram normalization method 388 
resulted in 869 proteins that are differentially expressed following the treatment with DHT. A 389 
supplementary filtration, allowing only the proteins quantified with at least 2 peptides/protein 390 
was chosen for further bioinformatics analysis. This resulted in a list of 258 proteins with 391 
spectral abundance alteration of at least 1.5-fold (DHT treatment/control samples) and 392 
statistical significance (Fig 8-b). Amongst them, four proteins which presented very high 393 
identification confidence (Mascot score>9000) and significant spectral alteration levels 394 
(Table 3) were found to be part of a key cell motility-signaling map, the regulation of actin 395 
cytoskeleton (KEGG entry hsa04810). This pathway was found to be statistically over-396 
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represented, after the implementation of a further significance correction, which was based on 397 
the false discovery rate algorithm (FDR p-value: 1.96E-2).  398 
 399 
  Discussion  400 
 The pluripotent nature of adult MSC is of great therapeutic interest to treat heart 401 
damage following myocardial infarction, reperfusion injury succeeding ischemia and 402 
heart/vascular damage. Certainly, it may provide the only alternative to heart transplantation 403 
as a permanent cure for heart damage (Nesselmann et al. 2008; Karantalis & Hare 2015; 404 
Singh et al. 2016).  The availability of MSC from multiple body sources and the fairly simple 405 
in vitro propagation of the cells to the desired cell type as well as the lack of ethical problems 406 
has made these cells a favorite source for stem cell therapy. The last decade has seen multiple 407 
animal and clinical studies assessing the efficacy of MSC in repairing damaged heart (Singh 408 
et al. 2016). Although, MSC induced protective effects were observed in most, but not all, 409 
studies, the consensus is that the integration of MSC is low and novel strategies promoting 410 
their homing in and integration need to be further developed to make MSC therapy successful.   411 
Sex steroids are known to directly affect human bone marrow stromal cells; however, 412 
the biological mechanisms involved remain unclear. In vitro experiments revealed that male 413 
sex hormones, i.e. androgens, induce endothelial cell growth, suggesting that androgens may 414 
influence the cardiovascular system via angiogenic actions (Sieveking et al. 2010). Thus, we 415 
set up experiments to find out whether exposure of MSC to androgens have a beneficial effect 416 
on the cell’s characteristic functions. In prior experiments, we have used testosterone 417 
(Corotchi et al. 2016) to assess its effects on the growth of MSCs. We found that the growth 418 
stimulatory effects of testosterone and DHT were comparable, although testosterone was 419 
marginally more potent than DHT (MSC growth was induced, by approximately 3.86 fold and 420 
3.4 fold, in response to testosterone and DHT respectively). Hence, for further experiments, 421 
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we employed DHT because it is a most potent testosterone derivative with the high affinity 422 
for androgen receptor and it is not metabolized to estradiol.   423 
 424 
The following novel findings were revealed by our experiments with MSCs: (a) DHT 425 
increased proliferation, migration and chemotaxis via mechanism(s) involving ARs; (b) DHT 426 
modulated MMP2 and MMP9 levels; (c) enhanced cell migration towards cardiac tissue, and 427 
(c) secretion of Angiogenin, VEGF, and NO, key factors involved in the invasion and 428 
integration of cells into ischemic tissue that attempts to regenerate.  429 
 We found that the secretion of MMPs is increased significantly in DHT-treated MSC, 430 
and this effect was specifically enhanced in the presence of heart slices. These results suggest 431 
the possibility that factors generated by ischemic tissue stimulates MSC to increase the MMPs 432 
production, and this response supports the proteolytic activity (see Fig 9), which is essential 433 
for clearing damaged scar tissue so as to facilitate MSC integration and tissue repair. Taken 434 
together the above findings suggest that DHT potentiates the integration of MSC into cardiac 435 
tissue and thus, may positively influence the repair process. 436 
  The participation of MMP’s and VEGF in angiogenesis is well established as they 437 
facilitate the cell migration and are pro-angiogenic factors (Ries et al. 2007; Mias et al. 2009). 438 
The spatio-temporal regulation of MMP-2 and MMP-9 have been observed, following 439 
myocardial infarction and end stage heart failure suggesting that they are involved in the 440 
cardiovascular remodeling (Deschamps & Spinale 2006).  Secreted MMPs are key markers 441 
for cell migration under normal and pathological conditions (Spinale & Wilbur 2009). 442 
Increased presence of MMP-2 is indicative of deleterious recovery following ischemic heart 443 
injury, whereas, sustained expression of MMP-9 facilitates recovery and post-ischemic heart 444 
reconstruction (Cheung et al. 2000). Our observation that DHT induced MMP-9, but not 445 
MMP-2 in MSCs suggests that DHT induces beneficial MMPs under normal conditions. The 446 
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fact that MMP-2 secretion was induced, when MSCs were co-incubated with heart slices 447 
suggests that factors generated from sliced (injured) heart trigger MMP-2 generation to 448 
potentially facilitate early proteolytic activity for clearing the scar tissue and to facilitate 449 
subsequent angiogenic and tissue growth/integration process (Ries et al 2007; Mishra et al., 450 
2013; Nam et al., 2015). The observation that DHT attenuated MMP-2 expression in MSCs 451 
co-incubated with heart slices after 48 hours, but increased MMP-9 expression suggests that 452 
DHT regulates MMP-2 and MMP-9 in a spatio-temporal fashion to facilitate tissue recovery.  453 
 454 
            Both MMP-2 and MMP-9 possess gelatinase activity and have a considerable overlap 455 
in substrates they degrade, however MMP-9 is incapable of direct proteolysis of collagen I 456 
(Klein & Bischoff 2011). Evidence also suggests that MMP-2 and MMP-9 have distinct role 457 
in tissue remodeling and these effects are regulated in a spatio-temporal fashion by paracrine 458 
factors generated following injury (Klein & Bischoff 2011; Ries et al., 2007; Nam et al., 459 
2015; Mishra et al. 2013). Knock-out models of MMP-9 exhibit delayed apoptosis, 460 
vascularization and ossification of hypertrophic chondrocytes. MMP-2 degrades extracellular 461 
matrix (ECM) protein and cleaves other non-ECM substrates including pro-TNF, FGF 462 
receptor-1, TGF-B, IL-1B and various chemokines. Our results showing observation that 463 
Treatment with DHT increased the expression of MMP-2, MMP-9 and EMMPRIM in MSC 464 
suggest that androgens can potentially activate mechanisms critical for initiating tissue repair 465 
and remodeling. This would be similar to the reported sprouting angiogenesis in endothelial 466 
cells, which release proteolytic enzymes, including MMPs and VEGF in order to induce 467 
efficiently angiogenic signaling (Wu et al. 2007; Cai et al. 2016). Our findings also 468 
demonstrate that the stimulatory effects of DHT on the expression of both, cell migration and 469 
pro-angiogenic factors, such as MMP-2, MMP-9, VEGF and Angiogenin are maintained up to 470 
48 hours. These results imply that MSC could be involved in angiogenesis either through 471 
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differentiation or via a paracrine effect. Furthermore, we demonstrate that DHT enhanced 472 
chemotaxis of MSC towards the cardiac slices and stimulated their adhesion and integration 473 
within this tissue. Our findings suggest that synthesis of MMPs is potentially influenced by 474 
EMMPRIN, could regulate myogenic cell differentiation; (Mohamed et al. 2011)) and provide 475 
the first evidence for an association between EMMPRIN and MMPs in a co-culture model 476 
using hormone-treated MSC.  477 
            At the functional level, our results demonstrate that cultured human MSC are capable 478 
of synthesizing NO constitutively. Moreover, we provide evidence that stimulation of MSC 479 
with androgens increased the NO release as measured in real-time in the culture medium and 480 
this secretion is blocked in presence of the AR antagonist. The significance of the increase in 481 
constitutive NO production in MSC can only be speculated. Since NO is a key mediator for 482 
angiogenesis (Losordo & Isner 2001), we assume that stimulation of basal NO production by 483 
DHT in human MSC participates in promoting/improving the capillary network around the 484 
ischemic sites. Our observation that DHT induces both VEGF and NO suggests that the pro-485 
angiogenic effects of DHT may be mediated via a cross talk between them. Moreover, this 486 
may create a synergistic environment as VEGF has been shown to induce angiogenesis via 487 
NO generation and NO induces VEGF thereby creating a positive feedback angiogenic loop 488 
(Papapetropoulos et al. 1997; Losordo & Isner 2001; Ikeda et al. 2012)  489 
The experiments showing that the number of DHT-treated MSC integrated in the 490 
cardiac slices was higher than that of non-treated cells provide evidence that the hormone 491 
facilitates homing-in and integration of MSC. The fact that quantification of the integrated 492 
cells was assessed using 2-D techniques which monitor cells stained within the 2nd or 3rd layer 493 
at a depth of ≈ 2 µm within the tissue reaffirms the notion that DHT promotes MSC 494 
integration deep within the tissue and the changes observed are not simply due to superficial 495 
MSC adherence. Although our findings provide evidence that DHT increases MSC 496 
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integration, whether the cells differentiate into endothelial or cardiomyocytes was not 497 
ascertained. Based on pilot studies treatment of MSC with DHT did not change the cell’s 498 
phenotype; however, whether they change while residing within the tissue environment 499 
remains unknown. Since the studies were conducted for a maximum of 72 hours because of 500 
limited cardiac sections viability, it is unlikely that the MSC differentiate into ECs or cardiac-501 
myocytes. The secretion of MMPs and pro-angiogenic molecules by MSCs indicates the pro-502 
angiogenic potential of hormone-stimulated cells. Further long-term studies are required to 503 
monitor the fate of DHT-stimulated MSC in the heart. 504 
The mass-spectrometric results identified integrin β1 as differentially regulated (1.8 505 
fold) by the DHT treatment. This is concurrent with other findings which demonstrate that β 506 
integrins are essential in MSC attachment to tissue lesions (Zwolanek et al. 2015). In addition, 507 
the DHT-induced up-regulation of myosin-9 could have a possible implication in the 508 
increased actomyosin assembly contraction. Together, these and other proteins (Table 3) 509 
participate in actin cytoskeleton rearrangement processes, data that corroborate well with our 510 
findings that MSC migration is enhanced by the DHT treatment. 511 
The clinical relevance of our findings can only be speculated. For instance, DHT may 512 
be of therapeutic relevance in enhancing MSC integration and cardiac repair. Our findings 513 
suggest that priming of MSC may amplify the chances of their success to repair a damaged 514 
heart. However, additional in vivo studies are necessary to confirm this possibility.  Although, 515 
our findings suggest that DHT may promote MSC induced cardiac repair, androgen 516 
substitution in elderly men has been shown to induce both deleterious (Budoff et al. 2017)and 517 
protective actions in older men (Ikeda et al. 2005, 2012b; Liu et al. 2014).  Moreover, 518 
androgens as well as ARs have been shown to induce cardiac growth, and drop in androgen 519 
levels is associated with cardiovascular disease (Dubey et al. 2002). Since MSC integration 520 
would require short-term exposure to DHT primed MSCs, it is feasible that its beneficial 521 
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actions may override its, potential, long-term deleterious effects.  However, in vivo studies are 522 
required to confirm this possibility. 523 
Although, our in vitro findings provide evidence that DHT promotes MSC integration 524 
in cardiac tissue, in vivo proof for this is still lacking.  Another limitations of the study include 525 
the fact that impact of androgens, whether beneficial or deleterious, on the cardiovascular 526 
system is still unclear (Budoff et al. 2017; Ikeda et al. 2005, 2012b; Liu et al. 2014). It is 527 
feasible that short term treatment with DHT primed MSC may not have the same deleterious 528 
effects as in subjects taking androgen substitution, however, this possibility needs to be 529 
further investigated.  MSC can evolve into many different cell types, including bone cells 530 
(Zomorodian & Baghaban Eslaminejad 2012). Since calcification of the blood vessels leads to 531 
cardiovascular disease, the treatment with MSC should be cautiously controlled for the 532 
possible deleterious side effects, and needs to be further investigated.  533 
Finally, the rationale for using 30nM DHT concentrations in the present study was that 534 
the value was comparable to testosterone. Moreover, unlike testosterone, DHT is not 535 
metabolized to estradiol thereby resulting in AR specific actions. However, it should be noted 536 
that circulating levels of DHT are 10 fold lower (≈ 3nM) and its affinity for AR is ≈ 3 fold 537 
higher. Hence, the concentrations in the present study may not represent levels that would 538 
result in the typical androgenic response. However, our finding that NO synthesis was 539 
induced by low (1nM) as well as high (30 and 100 nM) concentrations of DHT suggests that 540 
the effects of 30nM are AR mediated. Moreover, in preliminary growth studies physiological 541 
concentrations of DHT induced MSC growth and migration, suggesting that the effects of 542 
high 30nM DHT were mimicked by physiological concentrations of DHT.  Our contention 543 
that 30nM DHT induces pro-angiogenic factors and assists homing of MSCs into cardiac 544 
tissue, is supported by findings from Borst et al, who demonstrated that supra-physiologic 545 
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testosterone treatment improved recovery from cardiac ischemic reperfusion injury ((Borst et 546 
al. 2010)).  547 
Although our findings suggest that culturing MSC with DHT may allow for better 548 
incorporation into cardiac tissue, in a manner independent from systemically elevated 549 
androgen concentrations. However, from a translational perspective, some preclinical and 550 
clinical evidence indicates that DHT may be detrimental to cardiac function.  For example, 551 
Shores et al. reported that high circulating DHT is associated with cardiovascular disease and 552 
all-cause mortality in men. Rubio-Gayosso et al. also reported that 5alpha-reductase inhibition 553 
resulted in myocardial protection after cardiac ischemic reperfusion injury and that DHT 554 
treatment increased myocardial damage resulting from ischemic reperfusion injury. Hence, 555 
more studies using physiologic concentrations of DHT are required to further test its impact 556 
on tissue remodeling and cardiovascular repair.  557 
      558 
 In conclusion, we provide the first evidence that DHT induces growth, 559 
proliferation and migration of MSC and promotes integration of these cells into cardiac tissue 560 
in vitro. These effects are accompanied by up-regulation of ARs and of key molecules known 561 
to promote tissue remodeling and angiogenesis (EMMPRIN, MMP-2, MMP-9, VEGF, 562 
Angiogenin, NO). Our findings suggest that priming of MSC with DHT may functionally 563 
increase their capability to repair and regenerate cardiac tissue. However, in vivo studies using 564 
DHT primed MSC are necessary to confirm our in vitro observations.  565 
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Figure 1: Exposure of MSC to DHT maintains the cell morphology but increases significantly their 
proliferation. A) Morphology of cultured non-treated MSC (a, b) and of MSC exposed in vitro to DHT (c, 
d). Compared to controls (day 1), at 4 days DHT enhances proliferation, maintains the cell phenotype and is 
non-toxic for cells. B) Proliferation of MSCs (7000cells/ well) grown in DMEM 10/00 +10 % FBS + 1% 
Antibiotics in the absence (control) or presence of DHT or exposed to vehicle only, for 160 hours. As 
assessed by the cell index value, the proliferation of DHT-stimulated MSC (green) increases steadily and is 
above the values of non-stimulated cells (blue) or vehicle-exposed cells (green) for 160 hours. C) 
Determination of MSC proliferation using DNA quantification-CyQuant®. The cells (7000 cells/well) were 
cultured in DMSO (DHT-vehicle) or in the presence of DHT (MSC+DHT) and after 6 days, lysed and 
prepared for DNA quantification according to the manufacturer instructions. Note that DHT induces a 
significant increase in the number of MSC compare to controls. *p<0.05, n=3. 
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Figure 2.  Exposure of MSC to 30 nM DHT (MSC+DHT) increases gene expression of androgen receptors 
(AR, a), EMMPRIN (b) and MMP-9 (d) and does not affect MMP-2 mRNA (c). The quantification of gene 
expression was done by qRT-PCR assay. Data are expressed as means of fold expression (relative 
quantification) values (±) SEM of each gene in comparison with GAPDH and normalized to an arbitrary 
value of 1. Significant p values are indicated in the graphics and calculated from arbitrary value ANOVA 
tests. n=3. *p value < 0.05 
Table 1. qRT-PCR primers used for gene expression detection of MSC. Primers were obtained 
using the PerlPrimer V1.1.21 software. 
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Figure 3. DHT increases significantly the protein levels of AR, EMMPRIN, MMP-9 and Angiogenin in 
MSC. Cultured cells were stimulated with 30nM DHT and subjected to Western blot assay. As shown above 
by gel electrophoresis and morphometric analysis, compared to non-stimulated MSC (controls), DHT 
induces a significantly increase in protein expression of androgen receptor (a, AR), EMMPRIN (b), MMP-9 
(d) and Angiogenin (f) and has no effect on MMP-2 (c) and VEGF (e).  All the results were normalized to 
beta-Actin; *p value < 0.005 in comparison with control cells were considered statistically significant. n=3. 
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        Figure 4: DHT-treated MSC exhibit augmented NO release. The cells were exposed in culture either to 
different concentration of DHT (1, 30, 100 nM) (a) either to Flutamide (F) and DHT (b). NO release was 
determined in the culture medium using an amperometric NO sensor. Each measurement was done 
separately for t = 10 min; Baseline is considered 0 nM. 
 
 
 
 
 
Table 2. Quantification and statistical analysis of the NO concentration in the culture medium 
of MSC exposed to 1, 30 and 100 nM DHT in the absence or presence of Flutamide. Note that 
at all DHT concentrations used, Flutamide blocks the NO values indicating that, also 
androgen receptors are implicated in NO stimulation; n=4. 
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 Figure 5 a, b. Migration of MSC towards murine ventricular slices is significantly increased by 
prior exposure of the cells to DHT. As revealed by real-time based measurements (xCelligence 
system) for 14 hours. The cell index that signifies the number of cells that migrate towards the 
heart slices (Hs) shows increased migration of DHT-treated MSC (green) towards the murine Hs 
compared to non-treated MSC (blue), vehicle treated MSC (red) and Flutamide (Androgen 
receptor inhibitor) treated MSC (pink). Experiments were done in quadruplicate for at least three 
times. 
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Figure 6. Identification of the integration of DHT-treated MSC into the heart tissue slices by 
immunohistochemistry. MSC were co-cultured for 48 h with heart tissue slices (250 micrometer thick) 
and then the tissue was washed and embedded in paraffin. The 2 micrometer sections were incubated 
with anti-human nuclei antibody followed by an HRP-labeled secondary antibody. The peroxidase 
reaction stains in brown the MSC nuclei, whereas the Hematoxylin stains the mouse cell nuclei in blue. 
Note that in comparison with non-stimulated MSC (a), a significantly higher number of nuclei are 
stained (brown) in the heart slices co-cultured with DHT-stimulated human MSC (b).  As antibody 
control the IgG isotype was employed (c). In (d) digital counting of the results using ImageJ software 
shows that the number of stained human MSC nuclei is significantly higher in the case of stimulated cells 
(MSC+DHT).  For each section, 4 different fields were analyzed (n=3).  (e). Quantification of the 
number of MSC adhered/integrated into heart slices after co-culture for 48 hours assessed by human 
DNA analysis (qRT-PCR). n=3. *<0,05 as compared to non-treated cells. 
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Figure 7. Secretion of MMP-2 (a, b), MMP-9 (c, d), Angiogenin (e) and VEGF (f) by DHT-treated (30 nM) 
MSC kept in indirect contact with heart tissue slices (Hs) is significantly increased compared to controls 
(non-stimulated MSC). The experiments were performed in Transwell plates, for 24 and 48 hours, and the 
proteins were quantified by ELISA and Luminex assay using human antibodies (to evidence human MSC). 
p*<0,05; **<0,001, ##p value < 0.005 in comparison with control cells (non-stimulated) were considered 
statistically significant. n=3. 
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Figure 8: Nano chromatography mass spectrometric analysis of non-treated control MSCs and DHT-treated 
MSCs. a) Qualitative analysis revealed the identification of 3180 proteins, of which 370 proteins were only 
attributed to non-treated MSCs, while 490 proteins were uniquely identified in the samples following DHT 
treatment; b) The label-free relative mass spectrometric quantification demonstrated the spectral abundance 
alteration of 869 proteins (blue dots), 258 of them being quantified with at least 2 peptides/protein (dark-blue 
dots), passing the abundance ratio (vertical lines signify the log2 normalized ratio of 0.67 and 1.5, 
respectively) and the significance criteria (horizontal line represents the –log10 p-value of 0.05). 
Table 3: Spectral abundance alteration level and significance of the proteins that determined the statistical 
over-representation of regulation of actin cytoskeleton KEGG signaling pathway. Data includes also the 
Uniprot database accession entry, molecular weight and median Mascot identification score. ***p < 0,001 
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Figure 9: Schematic representation of DHT-induced pro-repair mechanisms in MSCs. Our data indicate that  
DHT stimulates proliferation and migration of MSC by a process in which increased  expression of 
EMMPRIN, MMP-9 potentially promote their homing in and cardiac integration. Additionally, DHT induces 
expression of Angiogenin, VEGF and of AR-dependent NO release that may participate in the process of 
angiogenesis and vasculogenesis.   
 
    
 
 
